MIR4635: A Potential Drug Target and Biomarker for Obesity (G100616479)

MIR4635: A Potential Drug Target and Biomarker for Obesity

Obesity is a significant public health issue, with an estimated global prevalence of over 1.9 billion people. The increasing obesity crisis has led to a range of health problems, including cardiovascular diseases, diabetes, and certain cancers. Therefore, identifying potential drug targets and biomarkers for obesity is crucial for developing effective treatments. In this article, we will explore MIR4635, a potential drug target and biomarker for obesity.

MIR4635 is a gene that encodes a protein named mir4635. Mir4635 is expressed in human tissues and has been shown to play a role in the regulation of energy metabolism and metabolism-associated genes (RAS/MAPK signaling pathway). Mir4635 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion.

MIR4635 has been identified as a potential drug target for obesity because of its involvement in the RAS/MAPK signaling pathway. The RAS/MAPK signaling pathway is a well-established signaling pathway that regulates various cellular processes, including inflammation, cell growth, and energy metabolism. Therefore, targeting this pathway may be a promising strategy for treating obesity.

Studies have shown that MIR4635 is highly expressed in human obese tissues, including fat tissues, and that it is involved in the regulation of obesity-related genes. In addition, animal models of obesity have shown that overexpression of MIR4635 can increase the body weight and obesity-related symptoms. Therefore, MIR4635 may be a promising biomarker for assessing the effectiveness of obesity treatments.

Furthermore, MIR4635 has been shown to be involved in the regulation of lipid metabolism, which is a crucial aspect of obesity. Obesity is often associated with abnormal lipid profiles, including high levels of triglycerides and low levels of HDL cholesterol. Therefore, targeting MIR4635 may be a promising strategy for treating obesity-related diseases.

In addition to its potential role in treating obesity, MIR4635 has also been shown to have potential biomarker properties. The Mir4635 gene has been shown to be involved in the regulation of cellular processes, including cell adhesion and migration. Therefore, Mir4635 may be a useful biomarker for assessing the effectiveness of treatments for obesity.

In conclusion, MIR4635 is a gene that has been identified as a potential drug target and biomarker for obesity. The RAS/MAPK signaling pathway is a promising target for treating obesity, and MIR4635 has been shown to be involved in this pathway. Furthermore, MIR4635 has also been shown to be involved in the regulation of lipid metabolism and may be a useful biomarker for assessing the effectiveness of treatments for obesity.

While further research is needed to fully understand the potential of MIR4635 as a drug target and biomarker for obesity, its potential implications are significant. The identification of MIR4635 as a potential drug target and biomarker for obesity opens up new avenues for the development of effective treatments for this debilitating disease.

Protein Name: MicroRNA 4635

The "MIR4635 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4635 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711 | MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740